Lindsay Howard, DO
Psychiatry · Portland, ORNPI 1497140438
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 37.9% of the total. Reporting peaked in 2021 at $402 and has fallen 96.1% since, to $16 in 2023.
Across 27 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$231
- Otsuka America Pharmaceutical, Inc.$126
- Alkermes, Inc.$90
- Takeda Pharmaceuticals U.S.A., Inc.$45
- Indivior Inc.$37
- AbbVie$29
- plus $51 from 3 others
What the payments were for
- Food & beverage$609100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $231 |
| Otsuka America Pharmaceutical, Inc. | 7 | $126 |
| Alkermes, Inc. | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Indivior Inc. | 2 | $37 |
| AbbVie | 2 | $29 |
| Lundbeck LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$125
How this compares
$609 in reported general payments places this provider in the 85th percentile of 366 psychiatry providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 35 | $1,141 |
| Divalproex Sodium | 24 | $957 |
| Bupropion XlBupropion Hcl | 49 | $933 |
| Clonazepam | 111 | $896 |
| Lurasidone Hcl | 11 | $848 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $738 |
| Duloxetine Hcl | 37 | $636 |
| Fluoxetine Hcl | 43 | $521 |
| Trazodone Hcl | 33 | $440 |
| Buspirone Hcl | 32 | $429 |
| Quetiapine Fumarate | 28 | $410 |
| Mirtazapine | 16 | $242 |
| Olanzapine | 19 | $154 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $144 |
| Gabapentin | 28 | $126 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Portland
- Alisha MorelandPortland$20K
- Leigh Anne BresslerPortland$15K
- Alfred LewyPortland$9K
- Anca Maria BejenaruPortland$6K
- Shondell DiazPortland$3K
- Jerzy HubertPortland$3K
- Kara PrussingPortland$3K
- Lyle JobePortland$3K
- Jon MessingerPortland$1K
- Allegra CondiottePortland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.